Adaptive Pharmacogenomics, LLC

Pediatr Nephrol. 2010 May;25(5):965-9

Authors: Leroy S, Isapof A, Fargue S, Fakhoury M, Bensman A, Deschênes G, Jacqz-Aigrain E, Ulinski T

Tacrolimus is known to potentially lead to adverse events in recipients with diarrhoea and/or calcium channel blocker (CCB) co-administration.

Pharmacogenet Genomics.

[60 years of medical genetics in Israel]

Harefuah. 2010 Feb;149(2):91-4, 124

Authors: Shalev SA, Borochowitz ZU, Zlotogora J

The principle deeds of genetics in Israel consist of a wide array of disciplines including agriculture, nutrients, biotechnology, pharmacology and pharmacogenetics, pertaining to criminal as well as medical aspects.

MassBio asked Mark Levin, a partner at Third Rock Ventures for his thoughts on the economic climate, the future of venture capital and hot new science. Here's what he had to say.

Q: It has been said that Third Rock looks for “Big Science” to invest in. As you look to the next 10 years out, what do you see now that has the capability to qualify as "big science?"

A: Well I guess a couple things. Certainly that’s true; we do look for big science. We also try to balance the portfolio.

Clin Chem Lab Med. 2010 Apr;48(4):447-59

Authors: Di Francia R, Frigeri F, Berretta M, Cecchin E, Orlando C, Pinto A, Pinzani P

BACKGROUND: Genotyping is crucial for the identification of genetic markers underlying the development of neoplastic diseases and for determining individual variations in response to specific drugs.

Soc Stud Sci. 2010 Apr;40(2):163-86

Authors: Hedgecoe A

Over the past few years, considerable interest has been paid to the way in which social expectations (hopes, hypes, fears) about new genomic technologies help shape, and in themselves are shaped by, emerging technologies, regulatory regimes and social concerns.

AIDS Rev. 2010 Jan-Mar;12(1):15-30

Authors: Vidal F, Gutiérrez F, Gutiérrez M, Olona M, Sánchez V, Mateo G, Peraire J, Viladés C, Veloso S, López-Dupla M, Domingo P

The availability of highly active antiretroviral therapy has markedly improved the survival rate and quality of life in patients infected with HIV.

CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22

Authors: Ray LA, Chin PF, Miotto K

Naltrexone is an opioid receptor antagonist with established efficacy, albeit moderate, for the treatment of alcohol dependence.

New findings at Nanjing University lead to a completely new standard for milk quality control, and possible new milk products with specific usage in the future.

Researchers have discovered a biomarker that could help in the treatment of patients with an aggressive type of lung cancer. Using a particular biomarker, researchers might better predict which patients with small cell lung cancer are resistant to existing drug therapies, and which ones could benefit from new therapies tailored to their specific needs.